Triggering innate immune receptors as new therapies in alzheimer’s disease and multiple sclerosis

9Citations
Citations of this article
37Readers
Mendeley users who have this article in their library.

Abstract

Multiple sclerosis and Alzheimer’s disease are two complex neurodegenerative diseases involving the immune system. So far, available treatments provide at best mild improvements to patients’ conditions. For decades now, a new set of molecules have been used to modulate and regulate the innate immunity in these pathologies. Most studies have been carried out in rodents and some of them have reported tremendous beneficial effects on the disease course. The modulation of innate immune cells is of great interest since it provides new hope for patients. In this review, we will briefly overview the therapeutic potential of some molecules and receptors in multiple sclerosis and Alzheimer’s disease and how they could be used to exploit new therapeutic avenues.

Cite

CITATION STYLE

APA

Piec, P. A., Pons, V., & Rivest, S. (2021, August 1). Triggering innate immune receptors as new therapies in alzheimer’s disease and multiple sclerosis. Cells. MDPI. https://doi.org/10.3390/cells10082164

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free